ProCE Banner Activity

CARTITUDE-1 Update: Phase I/II Trial of Ciltacabtagene Autoleucel for Heavily Pretreated Relapsed/Refractory Multiple Myeloma

Capsule Summary
Conference Coverage
Slideset

Cilta-cel demonstrated durable treatment responses for heavily pretreated patients with relapsed/refractory multiple myeloma with a median PFS of 34.9 months. 

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis